Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 1
2011 1
2013 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Advanced trauma life support (ATLS®): the ninth edition.
ATLS Subcommittee; American College of Surgeons’ Committee on Trauma; International ATLS working group. ATLS Subcommittee, et al. J Trauma Acute Care Surg. 2013 May;74(5):1363-6. doi: 10.1097/TA.0b013e31828b82f5. J Trauma Acute Care Surg. 2013. PMID: 23609291 No abstract available.
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
CRASH-2 trial collaborators; Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejía-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S. CRASH-2 trial collaborators, et al. Lancet. 2010 Jul 3;376(9734):23-32. doi: 10.1016/S0140-6736(10)60835-5. Epub 2010 Jun 14. Lancet. 2010. PMID: 20554319 Clinical Trial.
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
CRASH-2 collaborators; Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T. CRASH-2 collaborators, et al. Lancet. 2011 Mar 26;377(9771):1096-101, 1101.e1-2. doi: 10.1016/S0140-6736(11)60278-X. Lancet. 2011. PMID: 21439633 Clinical Trial.
Sebaceous lesions and their associated syndromes: part II.
Eisen DB, Michael DJ. Eisen DB, et al. Among authors: michael dj. J Am Acad Dermatol. 2009 Oct;61(4):563-78; quiz 579-80. doi: 10.1016/j.jaad.2009.04.059. J Am Acad Dermatol. 2009. PMID: 19751880 Review.
This syndrome encompasses a much broader spectrum of multisystem disorders, which is explored below. Muir-Torre syndrome is described as the presence of sebaceous tumors or keratoacanthomas with an underlying visceral malignancy. ...We discuss its relationship with Lynch s …
This syndrome encompasses a much broader spectrum of multisystem disorders, which is explored below. Muir-Torre syndrome is described …
Sebaceous lesions and their associated syndromes: part I.
Eisen DB, Michael DJ. Eisen DB, et al. Among authors: michael dj. J Am Acad Dermatol. 2009 Oct;61(4):549-60; quiz 561-2. doi: 10.1016/j.jaad.2009.04.058. J Am Acad Dermatol. 2009. PMID: 19751879 Review.
Controversies regarding these lesions will be explored, and any relationship with Muir-Torre syndrome will be discussed....
Controversies regarding these lesions will be explored, and any relationship with Muir-Torre syndrome will be discussed....